Drug Shortage Report for ACT BUPRENORPHINE/NALOXONE

Last updated on 2020-01-24 History
Report ID 95396
Drug Identification Number 02453908
Brand name ACT BUPRENORPHINE/NALOXONE
Common or Proper name ACT-BUPREN/NALOX TAB
Company Name TEVA CANADA LIMITED
Active Ingredient(s) BUPRENORPHINE NALOXONE
Strength(s) 2MG 0.5MG
Dosage form(s) TABLET
Route of administration SUBLINGUAL
Packaging size 30
ATC code N07BC
ATC description DRUGS USED IN ADDICTIVE DISORDERS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-10-02
Estimated end date 2020-01-31
Actual end date 2020-01-23
Shortage status Resolved
Updated date 2020-01-24
Company comments
Health Canada comments
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v8 2020-01-24 French Compare
v7 2020-01-24 English Compare
v6 2020-01-09 French Compare
v5 2020-01-09 English Compare
v4 2019-11-07 French Compare
v3 2019-11-07 English Compare
v2 2019-10-03 French Compare
v1 2019-10-03 English Compare